Objective:

To determine the chronic in vivo effects of empagliflozin on cardiomyocyte electrophysiology, excitation-contraction coupling (ECC), and transcriptome profile in a mouse model of HFpEF, highlighting its potential therapeutic implications.

Approach:

Key Findings:

• Empagliflozin treatment improved diastolic function and reduced proarrhythmogenic action potential changes, with specific metrics indicating the degree of improvement.
• Chronic treatment restored cardiomyocyte electrophysiology and ECC mechanisms, suggesting a reversal of pathological changes.
• Empagliflozin modified gene expression profiles in the heart, with implications for understanding its mechanism of action.

Interpretation:

Empagliflozin has lasting effects on cardiac function and gene expression in HFpEF, indicating potential therapeutic benefits beyond glycemic control, warranting further investigation in clinical settings.

Limitations:

• Study conducted in a specific mouse model, which may not fully represent human HFpEF, necessitating caution in extrapolation.
• Results may not be generalizable to other populations or treatment regimens, highlighting the need for diverse clinical trials.

Conclusion:

Empagliflozin demonstrates significant improvements in cardiac function and gene expression in a mouse model of HFpEF, suggesting its potential as a therapeutic agent in heart failure management.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.